Skip to main content
. 2026 Sep 3;43(10):3651–3673. doi: 10.1007/s11095-026-04186-1

Fig. 2.

Fig. 2

(a) Recorded flow rates and aerosol emission rates during the in vitro trials of the transnasal aerosol delivery systems operated at a target peak flow rate of 3 L/min, alongside the steady state approximation of the device flow rate used for CFD simulations. (b) Cumulative distribution of the initial particle sizes measured experimentally and used in the CFD simulations of the aerosol delivery to the infant nose-throat model.